Known targets — ChEMBL curated mechanism
CHRM1DRD2DRD3DRD4HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HTR2APDE3ASIGMAR1
The experimentally established mechanism targets of Lactic Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2A known ✓ | P28223 | 2/20 | 0.33 |
| ▸ | CHRM1 known ✓ | P11229 | 1/20 | 0.33 |
| ▸ | HRH1 known ✓ | P35367 | 1/20 | 0.33 |
| ▸ | DRD3 known ✓ | P35462 | 1/20 | 0.33 |
| ▸ | HDAC1 known ✓ | Q13547 | 1/20 | 0.33 |
| ▸ | HDAC2 known ✓ | Q92769 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 2/20 | 0.60 |
| ▸ | TP53 | P04637 | 1/20 | 0.55 |
| ▸ | THRB | P10828 | 1/20 | 0.35 |
| ▸ | AKR1C3 | P42330 | 2/20 | 0.33 |
| ▸ | AKR1C2 | P52895 | 1/20 | 0.33 |
| ▸ | AKR1A1 | P14550 | 1/20 | 0.33 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.33 |
| ▸ | HTR2C | P28335 | 1/20 | 0.33 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.33 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.33 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.33 |
| ▸ | PGD | P52209 | 1/20 | 0.33 |
| ▸ | PPARA | Q07869 | 2/20 | 0.33 |
| ▸ | PTGS2 | P35354 | 2/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Cadaverine Tartrate SCHEMBL7683551 | 0.88 | LMNA (0.57) | LMNATP53THRBAKR1C3AKR1C2 | |
| Bicarbonate SCHEMBL28942687 | 0.87 | LMNA (0.71) | LMNATP53THRBAKR1C3AKR1C2 | |
| Bicarbonate SCHEMBL5374586 | 0.87 | LMNA (0.71) | LMNATP53THRBAKR1C3AKR1C2 | |
| Bicarbonate SCHEMBL28895866 | 0.87 | LMNA (0.71) | LMNATP53THRBAKR1C3AKR1C2 | |
| Acetic Acid SCHEMBL23907968 | 0.84 | LMNA (0.67) | LMNATHRBTDP1 | |
| Bicarbonate SCHEMBL9453328 | 0.84 | LMNA (0.67) | LMNATP53THRBAKR1C3AKR1C2 | |
| Acetic Acid SCHEMBL222953 | 0.84 | LMNA (0.67) | LMNATHRBTDP1 | |
| SCHEMBL2023600 | 0.83 | LMNA (0.57) | LMNATP53THRBAKR1C3HTR2A | |
| Carbamic Acid SCHEMBL5387548 | 0.82 | LMNA (0.63) | LMNATHRBCHRM1CHRM3CYP2C9 | |
| Acetic Acid SCHEMBL8529879 | 0.82 | LMNA (0.63) | LMNATHRBTDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200399428-A1 | SYSTEMS, METHODS AND HYDROGELS FOR CELL CULTURE AND ANALYSIS | PHENOMEX INC. (US) | 2020-12-24 | — | — | US | claimed |
| EP-3681935-A2 | SYSTEMS, METHODS AND HYDROGELS FOR CELL CULTURE AND ANALYSIS | Evorion Biotechnologies GmbH (DE) | 2020-07-22 | — | — | EP | claimed |
| WO-2019048714-A2 | SYSTEMS, METHODS AND HYDROGELS FOR CELL CULTURE AND ANALYSIS | EVORION BIOTECHNOLOGIES GMBH (DE) | 2019-03-14 | — | — | WO | claimed |
| US-20040116709-A1 | Process for producing optically active n-aryl-1-amino-2-propanol derivatives | KANEKA CORPORATION (JP) | 2004-06-17 | — | — | US | claimed |
| EP-1367053-A1 | PROCESS FOR PRODUCING OPTICALLY ACTIVE N-ARYL-1-AMINO-2-PROPANOL DERIVATIVES | KANEKA CORPORATION (JP) | 2003-12-03 | — | — | EP | claimed |
| US-20200399428-A1 | SYSTEMS, METHODS AND HYDROGELS FOR CELL CULTURE AND ANALYSIS | PHENOMEX INC. (US) | 2020-12-24 | — | — | US | disclosed |
| US-20200282397-A1 | SYSTEMS, METHODS AND HYDROGELS FOR CELL CULTURE AND ANALYSIS | PHENOMEX INC. (US) | 2020-09-10 | — | — | US | disclosed |
| EP-3681935-A2 | SYSTEMS, METHODS AND HYDROGELS FOR CELL CULTURE AND ANALYSIS | Evorion Biotechnologies GmbH (DE) | 2020-07-22 | — | — | EP | disclosed |
| EP-3681636-A1 | SYSTEMS, METHODS AND HYDROGELS FOR CELL CULTURE AND ANALYSIS | Evorion Biotechnologies GmbH (DE) | 2020-07-22 | — | — | EP | disclosed |
| WO-2019048714-A2 | SYSTEMS, METHODS AND HYDROGELS FOR CELL CULTURE AND ANALYSIS | EVORION BIOTECHNOLOGIES GMBH (DE) | 2019-03-14 | — | — | WO | disclosed |
| EP-1367053-A4 | PROCESS FOR PRODUCING OPTICALLY ACTIVE N-ARYL-1-AMINO-2-PROPANOL DERIVATIVES | KANEKA CORP (JP) | 2005-08-03 | — | — | EP | disclosed |
| US-20040116709-A1 | Process for producing optically active n-aryl-1-amino-2-propanol derivatives | KANEKA CORPORATION (JP) | 2004-06-17 | — | — | US | disclosed |
| US-20040116709-A1 | Process for producing optically active n-aryl-1-amino-2-propanol derivatives | KANEKA CORPORATION (JP) | 2004-06-17 | — | — | US | disclosed |
| EP-1367053-A1 | PROCESS FOR PRODUCING OPTICALLY ACTIVE N-ARYL-1-AMINO-2-PROPANOL DERIVATIVES | KANEKA CORPORATION (JP) | 2003-12-03 | — | — | EP | disclosed |
| EP-1367053-A1 | PROCESS FOR PRODUCING OPTICALLY ACTIVE N-ARYL-1-AMINO-2-PROPANOL DERIVATIVES | KANEKA CORPORATION (JP) | 2003-12-03 | — | — | EP | disclosed |
| WO-2002070482-A1 | PROCESS FOR PRODUCING OPTICALLY ACTIVE N-ARYL-1-AMINO-2-PROPANOL DERIVATIVES | KANEKA CORPORATION (JP) | 2002-09-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200399428-A1 | SYSTEMS, METHODS AND HYDROGELS FOR CELL CULTURE AND ANALYSIS | HLCS, CD63, CD44 | HTR2A 3853/4885CHRM1 4857/4885HRH1 4252/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.